2023 World Conference on Lung Cancer (Posters)-EP07.05. CDDP/TS1 Followed by Maintenance TS1 as Adjuvant Chemotherapy in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer

EP07.05. CDDP/TS1 Followed by Maintenance TS1 as Adjuvant Chemotherapy in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This abstract summarizes a phase 2 clinical trial that assessed the feasibility and efficacy of adjuvant chemotherapy in patients with completely resected stage II/IIIA non-small cell lung cancer (NSCLC). The standard treatment for postoperative adjuvant chemotherapy in these patients is a platinum-based regimen, but the completion rate is often low due to side effects. The researchers wanted to evaluate the use of TS1, an oral anticancer drug with fewer side effects, as an adjuvant therapy. <br /><br />The trial enrolled 59 patients from multiple institutions between August 2013 and October 2018. The chemotherapy protocol consisted of three cycles of CDDP and TS1 followed by TS1 every other day until 12 months postoperatively. The primary endpoint of the study was the treatment completion rate, and the secondary endpoints were adverse events, 3-year recurrence-free survival, and overall survival rate.<br /><br />The results showed that the treatment completion rate for the planned protocol was 57.6%. The 3-year recurrence-free survival was 62.5%. The most common reasons for discontinuation of treatment were adverse events, refusal, tumor recurrence, and other reasons. No treatment-related deaths or grade 4 or higher adverse events were observed.<br /><br />Based on these findings, the researchers concluded that adjuvant chemotherapy with CDDP/TS-1 followed by TS-1 every other day may be feasible and improve treatment completion rates compared to the conventional method of taking TS-1 orally for 14 days followed by a 7-day rest. This treatment approach may have potential benefits in improving patient outcomes as postoperative adjuvant chemotherapy for completely resected stage II/IIIA NSCLC.<br /><br />In summary, this phase 2 clinical trial suggests that the use of TS1 as adjuvant chemotherapy in patients with completely resected stage II/IIIA NSCLC may be a viable option with improved completion rates and potentially beneficial outcomes.

Asset Subtitle

Kosuke Fujino

Meta Tag

Speaker Kosuke Fujino

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

adjuvant chemotherapy

completely resected

NSCLC

TS1

treatment completion rate

adverse events

recurrence-free survival

overall survival rate

chemotherapy protocol

feasible